CClinicalTrials.gg
Status unknownNCT01539772Updated Jun 15, 2018

Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping

An observational study in Becker Muscular Dystrophy, sponsored by Cooperative International Neuromuscular Research Group. Status unknown at 16 sites in 4 countries. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2018-06-15.

Sponsored by Cooperative International Neuromuscular Research Group · Observational

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
85
Ages
4 Years and older
Sex
Male
01

Study summary

This is a multi-center natural history study that will be conducted at participating centers in the Cooperative International Neuromuscular Research Group (CINRG). Following a baseline evaluation, participants will have three follow-up visits over a three-year period. The investigators will characterize the Becker muscular dystrophy phenotype, and correlate specific abnormal dystrophin proteins with the range of clinical outcomes.

Read the detailed description

We will utilize the Cooperative International Neuromuscular Research group (CINRG) network to collect cohorts of Becker muscular dystrophy (BMD) patients with in-frame deletions in the dystrophin gene. We will collect clinical data across multiple body systems and correlate these findings to the high-resolution deletion break-point mapping performed from the tissue samples. We will investigate the observed variability to deepen our understanding of molecular mechanisms relevant to the optimization of exon skipping therapeutic approaches.

02

Conditions studied

  • Becker Muscular Dystrophy
03

In context

Muscular Dystrophies

548 studies on the registry are indexed under Muscular Dystrophies; 89 are open to participants now.

This study's enrollment of 85 is above the median of 69 across 179 observational studies indexed under Muscular Dystrophies.

Browse Muscular Dystrophies studies →

Lead sponsor

Cooperative International Neuromuscular Research Group is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.

Inclusion criteria

  • Male
  • Age 4 or older
  • Diagnosis of BMD with an in-frame deletion in the dystrophin gene, where the boundaries of the mutations are confirmed.

Exclusion criteria

Exclusion Criteria:

  • Investigator assessment of inability to comply with protocol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
85 participants (actual)

Groups and cohorts

  • Becker

    BMD participants over 4 years of age with in-frame deletions in the dystrophin gene. .

06

What researchers measure

Primary outcomes

  1. Strength and function

    Time frame: Annual

  2. Quality of life

    These questionnaires include: * Pediatric Quality of Life Inventory (PedsQL) * Pediatrics and Adult Neuromuscular module Quality of Life (NeuroQOL)

    Time frame: Annual

  3. Medical history assessment - ambulation status, medication history, hospitalizations, surgeries, nutrition, fractures, and cardiac tests

    Time frame: Annual

07

Study locations

16 sites
  • University of California Davis
    Sacramento, California, United States
  • Children's National Health System
    Washington, District of Columbia, United States
  • University of Florida
    Gainesville, Florida, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois, United States
  • University of Minnesota
    Minneapolis, Minnesota, United States
  • Washington University
    Saint Louis, Missouri, United States
  • Carolinas Medical Center
    Charlotte, North Carolina, United States
  • Duke Children's Hospital and Health Center
    Durham, North Carolina, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
  • University of Tennessee
    Memphis, Tennessee, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9036, United States
  • Alberta Children's Hospital
    Calgary, Alberta, Canada
  • Centro Clinico Nemo
    Milan, Italy
  • Institute of Genetic Medicine - Newcastle University
    Newcastle upon Tyne, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01539772
Lead sponsor
Cooperative International Neuromuscular Research Group
Responsible party
Sponsor
First posted
Feb 28, 2012
Start date
Apr 2012
Primary completion
Aug 2018 (estimated)
Completion
Aug 2018 (estimated)
Last update
Jun 15, 2018

Study contacts

Paula R Clemens, MD
study chair · University of Pittsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion